Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome

Anne Line Engsbro, C Rune Stensvold, Henrik V Nielsen, Peter Bytzer

22 Citationer (Scopus)

Abstrakt

The role of Dientamoeba fragilis in irritable bowel syndrome (IBS) is incompletely known. We aimed to investigate whether eradication of D. fragilis alleviates symptoms in IBS. Twenty-five D. fragilis-positive IBS patients were treated with Metronidazole (MZ) or Tetracycline. The patients were mostly female (89%), and mean age (SD) was 35.1 (8.2) years. Microbiological response, evaluated 2 weeks post-treatment, was observed in 15 of 25 patients (60%), all by MZ. Clinical response, defined as adequate relief of symptoms, was observed in 7 of 22 patients (32%), all by MZ. In a logistic regression analysis, we found no significant association between clinical and microbiological response. This case study did not support our hypothesis of a simple association between D. fragilis and IBS. Some D. fragilis-infections were insufficiently treated by MZ. Further studies into the prevalence and effect of eradication of D. fragilis in IBS and into efficient treatments of D. fragilis are warranted.
OriginalsprogEngelsk
TidsskriftAmerican Journal of Tropical Medicine and Hygiene
Vol/bind87
Udgave nummer6
Sider (fra-til)1046-52
Antal sider7
ISSN0002-9637
DOI
StatusUdgivet - 2012
Udgivet eksterntJa

Fingeraftryk

Dyk ned i forskningsemnerne om 'Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome'. Sammen danner de et unikt fingeraftryk.

Citationsformater